BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

387 related articles for article (PubMed ID: 29280459)

  • 41. Dose escalation with stereotactic body radiation therapy boost for locally advanced non small cell lung cancer.
    Karam SD; Horne ZD; Hong RL; McRae D; Duhamel D; Nasr NM
    Radiat Oncol; 2013 Jul; 8():179. PubMed ID: 23842112
    [TBL] [Abstract][Full Text] [Related]  

  • 42. Long term efficacy and toxicity after stereotactic ablative reirradiation in locally relapsed stage III non-small cell lung cancer.
    Sumodhee S; Bondiau PY; Poudenx M; Cohen C; Naghavi AO; Padovani B; Maneval D; Gal J; Leysalle A; Ghalloussi H; Otto J; Doyen J
    BMC Cancer; 2019 Apr; 19(1):305. PubMed ID: 30943943
    [TBL] [Abstract][Full Text] [Related]  

  • 43. FDG PET/CT texture analysis for predicting the outcome of lung cancer treated by stereotactic body radiation therapy.
    Lovinfosse P; Janvary ZL; Coucke P; Jodogne S; Bernard C; Hatt M; Visvikis D; Jansen N; Duysinx B; Hustinx R
    Eur J Nucl Med Mol Imaging; 2016 Jul; 43(8):1453-60. PubMed ID: 26830299
    [TBL] [Abstract][Full Text] [Related]  

  • 44. Image guided hypofractionated 3-dimensional radiation therapy in patients with inoperable advanced stage non-small cell lung cancer.
    Osti MF; Agolli L; Valeriani M; Falco T; Bracci S; De Sanctis V; Enrici RM
    Int J Radiat Oncol Biol Phys; 2013 Mar; 85(3):e157-63. PubMed ID: 23182393
    [TBL] [Abstract][Full Text] [Related]  

  • 45. Outcomes and toxicity of stereotactic body radiation therapy for advanced stage ultra-central non-small cell lung cancer.
    Cong Y; Sun B; Wang J; Meng X; Xuan L; Zhang J; Liu J; Shen G; Wu S
    Thorac Cancer; 2019 Jul; 10(7):1567-1575. PubMed ID: 31187604
    [TBL] [Abstract][Full Text] [Related]  

  • 46. Cardiac Dose and Survival After Stereotactic Body Radiotherapy for Early-stage Non-Small-cell Lung Cancer.
    Tembhekar AR; Wright CL; Daly ME
    Clin Lung Cancer; 2017 May; 18(3):293-298. PubMed ID: 28089158
    [TBL] [Abstract][Full Text] [Related]  

  • 47. Long-Term Survival after Salvage Surgery for Local Failure after Definitive Chemoradiation Therapy for Locally Advanced Non-small Cell Lung Cancer.
    Schreiner W; Dudek W; Lettmaier S; Fietkau R; Sirbu H
    Thorac Cardiovasc Surg; 2018 Mar; 66(2):135-141. PubMed ID: 28992654
    [TBL] [Abstract][Full Text] [Related]  

  • 48. Pre-treatment FDG-PET predicts the site of in-field progression following concurrent chemoradiotherapy for stage III non-small cell lung cancer.
    Ohri N; Piperdi B; Garg MK; Bodner WR; Gucalp R; Perez-Soler R; Keller SM; Guha C
    Lung Cancer; 2015 Jan; 87(1):23-7. PubMed ID: 25468149
    [TBL] [Abstract][Full Text] [Related]  

  • 49. Residual ¹⁸F-FDG-PET uptake 12 weeks after stereotactic ablative radiotherapy for stage I non-small-cell lung cancer predicts local control.
    Bollineni VR; Widder J; Pruim J; Langendijk JA; Wiegman EM
    Int J Radiat Oncol Biol Phys; 2012 Jul; 83(4):e551-5. PubMed ID: 22417800
    [TBL] [Abstract][Full Text] [Related]  

  • 50. Stereotactic body radiotherapy for primary lung cancer at a dose of 50 Gy total in five fractions to the periphery of the planning target volume calculated using a superposition algorithm.
    Takeda A; Sanuki N; Kunieda E; Ohashi T; Oku Y; Takeda T; Shigematsu N; Kubo A
    Int J Radiat Oncol Biol Phys; 2009 Feb; 73(2):442-8. PubMed ID: 18990507
    [TBL] [Abstract][Full Text] [Related]  

  • 51. Outcome and toxicity of intensity modulated radiotherapy with simultaneous integrated boost in locally advanced non-small cell lung cancer patients.
    Fondevilla Soler A; López-Guerra JL; Dzugashvili M; Sempere Rincón P; Sautbaet A; Castañeda P; Díaz JM; Praena-Fernandez JM; Rivin Del Campo E; Azinovic I
    Clin Transl Oncol; 2017 Dec; 19(12):1469-1477. PubMed ID: 28589434
    [TBL] [Abstract][Full Text] [Related]  

  • 52. Stereotactic body radiation therapy for early-stage non-small-cell lung cancer in octogenarians and older: an alternative treatment.
    Bei Y; Murakami N; Nakayama Y; Okuma K; Kashihara T; Raturi VP; Okamoto H; Takahashi K; Inaba K; Igaki H; Itami J
    J Radiat Res; 2020 Jul; 61(4):586-593. PubMed ID: 32383730
    [TBL] [Abstract][Full Text] [Related]  

  • 53. Rationale and Protocol for a Canadian Multicenter Phase II Randomized Trial Assessing Selective Metabolically Adaptive Radiation Dose Escalation in Locally Advanced Non-small-cell Lung Cancer (NCT02788461).
    Raman S; Bissonnette JP; Warner A; Le L; Bratman S; Leighl N; Bezjak A; Palma D; Schellenberg D; Sun A
    Clin Lung Cancer; 2018 Sep; 19(5):e699-e703. PubMed ID: 29903551
    [TBL] [Abstract][Full Text] [Related]  

  • 54. Comparative effectiveness of aggressive thoracic radiation therapy and concurrent chemoradiation therapy in metastatic lung cancer.
    Koshy M; Malik R; Mahmood U; Rusthoven CG; Sher DJ
    Pract Radiat Oncol; 2015; 5(6):374-82. PubMed ID: 26412340
    [TBL] [Abstract][Full Text] [Related]  

  • 55. The treatment of stage III nonsmall cell lung cancer using high dose conformal radiotherapy.
    Sibley GS; Mundt AJ; Shapiro C; Jacobs R; Chen G; Weichselbaum R; Vijayakumar S
    Int J Radiat Oncol Biol Phys; 1995 Dec; 33(5):1001-7. PubMed ID: 7493826
    [TBL] [Abstract][Full Text] [Related]  

  • 56. An individualized radiation dose escalation trial in non-small cell lung cancer based on FDG-PET imaging.
    Wanet M; Delor A; Hanin FX; Ghaye B; Van Maanen A; Remouchamps V; Clermont C; Goossens S; Lee JA; Janssens G; Bol A; Geets X
    Strahlenther Onkol; 2017 Oct; 193(10):812-822. PubMed ID: 28733723
    [TBL] [Abstract][Full Text] [Related]  

  • 57. Helical image-guided stereotactic body radiotherapy (SBRT) for the treatment of early-stage lung cancer: a single-institution experience at the Willis-Knighton Cancer Center.
    Rosen LR; Fischer-Valuck BW; Katz SR; Durci M; Wu HT; Syh J; Syh J; Patel B
    Tumori; 2014; 100(1):42-8. PubMed ID: 24675490
    [TBL] [Abstract][Full Text] [Related]  

  • 58. Long term outcome after 48 Gy stereotactic ablative body radiotherapy for peripheral stage I non-small cell lung cancer.
    Dubaere E; Goffaux M; Wanet M; Bihin B; Gheldof C; Demoulin AS; Bolly A; Bustin F; Duplaquet F; Baugnee PE; Gustin M; Hers V; Maisin F; Marchand E; Ocak S; Pirard L; Vancutsem O; Van Neck E; Vandermoten G; Zaharia L; Remouchamps V
    BMC Cancer; 2019 Jun; 19(1):639. PubMed ID: 31253136
    [TBL] [Abstract][Full Text] [Related]  

  • 59. Feasible Optimization of Stereotactic Ablative Radiotherapy Dose by Tumor Size for Stage I Non-small-cell Lung Cancer.
    Lee S; Song SY; Kim SS; Choi W; Je HU; Back GM; Cho B; Jeong SY; Choi EK
    Clin Lung Cancer; 2018 Mar; 19(2):e253-e261. PubMed ID: 29196082
    [TBL] [Abstract][Full Text] [Related]  

  • 60. Stereotactic Body Radiation Therapy for Central Early-Stage NSCLC: Results of a Prospective Phase I/II Trial.
    Roach MC; Robinson CG; DeWees TA; Ganachaud J; Przybysz D; Drzymala R; Rehman S; Kashani R; Bradley JD
    J Thorac Oncol; 2018 Nov; 13(11):1727-1732. PubMed ID: 30056162
    [TBL] [Abstract][Full Text] [Related]  

    [Previous]   [Next]    [New Search]
    of 20.